Csl announces closing of global collaboration and licensing agreement with arcturus therapeutics

Csl to access late-stage next-generation mrna platform technology, enabling development of vaccines for covid-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens king of prussia, pa. , dec. 12, 2022 /prnewswire/ -- csl limited (asx:csl; usotc:cslly) today announced that its subsidiary, csl seqirus, finalized its global collaboration and license agreement with arcturus therapeutics holdings inc ("arcturus therapeutics"; nasdaq: arct).
ARCT Ratings Summary
ARCT Quant Ranking